Illumina (NASDAQ:ILMN) Price Target Increased to $430.00 by Analysts at SVB Leerink

Illumina (NASDAQ:ILMN) had its price objective increased by SVB Leerink from $420.00 to $430.00 in a report released on Tuesday, Price Targets.com reports. They currently have a market perform rating on the life sciences company’s stock. SVB Leerink also issued estimates for Illumina’s Q4 2021 earnings at $0.62 EPS, FY2021 earnings at $5.77 EPS, FY2021 earnings at $5.54 EPS, Q1 2022 earnings at $0.86 EPS, Q2 2022 earnings at $0.90 EPS, Q3 2022 earnings at $1.11 EPS, Q4 2022 earnings at $1.28 EPS, FY2022 earnings at $4.14 EPS and FY2023 earnings at $5.44 EPS.

ILMN has been the topic of a number of other research reports. Citigroup dropped their target price on shares of Illumina from $450.00 to $400.00 and set a neutral rating on the stock in a research report on Thursday, January 6th. Zacks Investment Research raised shares of Illumina from a strong sell rating to a hold rating and set a $399.00 target price on the stock in a research report on Tuesday, January 4th. Robert W. Baird dropped their target price on shares of Illumina from $493.00 to $437.00 and set a neutral rating on the stock in a research report on Monday, November 8th. TheStreet lowered shares of Illumina from a b- rating to a c rating in a research report on Wednesday, October 6th. Finally, Morgan Stanley initiated coverage on shares of Illumina in a research report on Thursday, January 6th. They set an equal weight rating and a $425.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $443.69.

Shares of Illumina stock opened at $405.14 on Tuesday. The firm has a fifty day simple moving average of $378.55 and a 200-day simple moving average of $428.48. The company has a current ratio of 2.68, a quick ratio of 2.24 and a debt-to-equity ratio of 0.16. Illumina has a 1-year low of $341.03 and a 1-year high of $555.77. The stock has a market capitalization of $63.32 billion, a price-to-earnings ratio of 66.53, a PEG ratio of 3.22 and a beta of 0.90.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, November 4th. The life sciences company reported $1.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.21. Illumina had a net margin of 21.17% and a return on equity of 15.03%. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the previous year, the company earned $1.02 earnings per share. Illumina’s revenue for the quarter was up 39.3% on a year-over-year basis. As a group, research analysts predict that Illumina will post 5.66 earnings per share for the current year.

In other news, SVP Charles Dadswell sold 314 shares of the company’s stock in a transaction dated Friday, October 22nd. The shares were sold at an average price of $411.00, for a total value of $129,054.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Alexander Aravanis sold 2,926 shares of the company’s stock in a transaction dated Tuesday, October 19th. The stock was sold at an average price of $411.82, for a total transaction of $1,204,985.32. The disclosure for this sale can be found here. Insiders sold a total of 12,189 shares of company stock worth $5,024,576 in the last three months. Insiders own 0.23% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Evermay Wealth Management LLC bought a new stake in shares of Illumina in the 2nd quarter worth about $26,000. Assetmark Inc. acquired a new position in Illumina during the 3rd quarter worth about $26,000. Activest Wealth Management acquired a new position in Illumina during the 2nd quarter worth about $35,000. Logan Capital Management Inc. lifted its position in Illumina by 90.7% during the 3rd quarter. Logan Capital Management Inc. now owns 82 shares of the life sciences company’s stock worth $33,000 after buying an additional 39 shares in the last quarter. Finally, Bell Investment Advisors Inc acquired a new position in Illumina during the 3rd quarter worth about $37,000. 84.89% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

Read More: VIX – Volatility Index

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.